Website Notice Block

Board of Directors

Stephen T. Wills C.P.A., M.S.T.
Executive Chairman

Mr. Wills currently serves as the chief financial officer and chief operating officer of Palatin Technologies, Inc., a publicly-held biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases in the fields of sexual dysfunction, anti-inflammatory targets and heart failure. He possesses extensive financial, operational and healthcare experience. Mr. Wills served as executive chairman and interim principal executive officer of Derma Sciences, Inc., a publicly-held company providing advanced wound care products, from December 2015 until February 2017 when Derma Sciences was acquired by Integra Life Sciences. Mr. Wills also served as the lead director until December 2015. Mr. Wills currently serves on the board of trustees and executive committee of The Hun School of Princeton. Mr. Wills, a certified public accountant, earned his B.S. in accounting from West Chester University, and an M.S. in taxation from Temple University.

    Vickie R. Driver

    Dr. Driver is board certified in foot surgery by the American Board of Podiatric Surgery and is a Fellow at the American College of Foot and Ankle Surgeons, licensed in Rhode Island. Her career as a podiatric physician and surgeon has included a special emphasis on limb preservation and wound healing in her medical practice, as well as, research and education. Dr. Driver is a Professor of Surgery in the Department of Orthopedics at Brown University (Clinical). She has served for 9 years on the Board of Directors for the Association for the Advancement of Wound Care ("AAWC"), and recently completed her tenure as president for this international organization. Dr. Driver is also the chair of Wound Care Experts and U.S. Food and Drug Administration (FDA) Clinical Endpoints Project.  She has just been named to serve as member at large to the Board of Directors of the Wound Healing Society (WHS) and Board Member to the Critical Limb Ischemia (CLI) Global Society. In addition, she serves on multiple clinical national and international committees that focus on preventing limb loss and improving wound healing in the high-risk population. She is considered an outspoken ambassador and patient advocate for lower extremity limb preservation and amputation prevention. She has served as an investigator for more than 70 important multi-center randomized clinical trials, as well as developed and supervised multiple research fellowship training programs. She has served and chaired multiple committees for large national and international pivotal clinical trials and has authored over 120 publications and abstracts. Dr. Driver is credited with the development and directorship of multiple major multidisciplinary Limb Preservation- Wound Healing Centers of Excellence, including Military/VA, Hospital and University based programs. She currently serves as Director, Translational Medicine, Wound Healing, Novartis Institute for Biomedical Research.

      David Fox
      David Fox has served as a member of our board of directors since April 2020. Mr. Fox was most recently a partner at Kirkland & Ellis LLP and served as a member of its Global Executive Management Committee until 2019. Prior to joining Kirkland, Mr. Fox was partner with Skadden, Arps, Slate, Meagher & Flom LLP, where he was a member of its top governing committee. Mr. Fox is a director of Israel Discount Bank of New York, a member of the board of directors at the Park Avenue Armory, and a member of the advisory board of New Alternatives for Children, for which he provides support to families caring for medically fragile children. In addition, Mr. Fox serves on the board of governors, and is an honorary fellow, of the Hebrew University, Jerusalem. He holds an LL.B. degree from Jerusalem University, Israel.
      Sharon Kochan

      Mr. Kochan has served as Executive Vice President & President, International, for Perrigo Company Plc. since 2012, and is a member of Perrigo Executive Committee since 2007.  Perrigo Company plc. is a global, multibillion, over-the-counter, consumer goods and specialty pharmaceutical company listed on the New York Stock Exchange. From March 2007 to July 2012, he served as Executive Vice President, General Manager of Prescription Pharmaceuticals for Perrigo and from 2005 to 2007, he was Senior Vice President of Business Development and Strategy for Perrigo. Mr. Kochan was Vice President, Business Development of Agis Industries (1983) Ltd. from 2001 until Perrigo acquired Agis in 2005.  He completed the Senior Management Program at the Technion Institute of Management (Haifa, Israel), received a Master of Science in Operations Research & Management Science from Columbia University (New York City) and received a Bachelor of Science in Industrial and Management Engineering from Tel-Aviv University (Tel-Aviv, Israel).

      Nissim Mashiach

      Mr. Mashiach served as President and Chief Executive Officer of Macrocure Ltd. from June 2012 to January 2017.  Macrocure was a Nasdaq listed biotechnology company focused on developing, manufacturing and commercializing novel cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds. From 2009 to 2012, he served as General Manager at Ethicon, a Johnson & Johnson company. Prior to Ethicon, he served as President and Chief Operating Officer at Omrix Biopharmaceuticals, Inc., a company acquired by Johnson & Johnson in 2008. Prior to Omrix, Mr. Mashiach held leadership positions at several pharmaceutical companies. He holds an MBA from the University of Manchester (Manchester, England), an MPharmSc from the Hebrew University (Jerusalem, Israel), and a B.Sc, Chemical Engineering from the Technion-Israel Institute of Technology (Haifa, Israel).

      Samuel Moed
      Samuel Moed has served as a member of our board of directors since April 2020. Prior to joining our board, Mr. Moed served as an executive at Bristol-Myers Squibb, a global biopharma company focused on innovative therapeutics. In his most recent capacity as Senior Vice President, Corporate Strategy, Mr. Moed led the strategic planning of the company in all major business activities worldwide. Previously, Mr. Moed oversaw strategy for BMS’ Worldwide Pharmaceuticals Group, encompassing a range of global strategic initiatives, and managed a global portfolio of strategic alliances. Among other positions, he served as President of U.S. Pharmaceuticals and as President of Worldwide Consumer Healthcare. Mr. Moed received a BA in history from Columbia University in New York City.
      Assaf Segal

      Mr. Assaf Segal is currently the Chief Financial Officer at Clal Biotechnology Industries, one of Israel’s leading investment companies with a portfolio of investments in biotechnology companies in Israel and the U.S. Before joining Clal Biotechnology in 2015, Mr. Segal was a Partner at Variance Economic Consulting for 11 years. He also has experience in corporate finance at Kesselman Corporate Finance - Price Waterhouse Coopers and served as the Head of Economic Department, North American Division at Amdocs. Mr. Segal received his Master in Business Administration in Finance & Information Systems and a B.A. in Economics and Statistics from The Hebrew University in Jerusalem, Israel.

        Ofer Gonen, B.Sc., MA Economic & Finance

        Mr. Gonen is in charge of business development of CBI’s portfolio companies, working closely with co-investors and strategic partners. He serves as board member at Andromeda, CureTech, MediWound, Polyheal, Braintact, Avraham, Campus Bio, Thrombotech and CLS. A veteran of Talpiot, a prestigious IDF unit, he accrued extensive technological and R&D experience in his military service, during which he was awarded the Israeli National Security Medal.

        Mr. Gonen received his MA in Economics and Finance from the Tel Aviv University and his BSc in Physics, Mathematics and Chemistry from the Hebrew University of Jerusalem.